(redirected from Lotrimin Ultra)


a topical antifungal agent used as the hydrochloride salt in the treatment of athlete's foot, jock itch, and ringworm.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


(byoo-ten-a-feen) ,

Lotrimin Ultra

(trade name),


(trade name)


Therapeutic: antifungals
Pregnancy Category: B


Treatment of a variety of cutaneous fungal infections, including tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor.


Affects the synthesis of the fungal cell wall.

Therapeutic effects

Decrease in symptoms of fungal infection.


Absorption: Absorption through intact skin is minimal.
Distribution: Distribution after topical administration is primarily local.
Metabolism and Excretion: Hepatic via hydroxylation.
Half-life: 35 hr.

Time/action profile

Topunknownup to 4 wkunknown


Contraindicated in: Hypersensitivity to active ingredients, additives, preservatives, or bases; Some products contain alcohol or bisulfites and should be avoided in patients with known intolerance.
Use Cautiously in: Nail and scalp infections (may require additional systemic therapy); Obstetric / Lactation: Safety not established.

Adverse Reactions/Side Effects


  • burning
  • itching
  • local hypersensitivity reactions
  • redness
  • stinging


Drug-Drug interaction

None significant.


Topical (Adults and Children > 12 yr) Apply once daily for 2 wk for patients with tinea corporis, tinea cruris, or tinea versicolor. Apply once daily for 4 wk or twice daily for 7 days for patients with tinea pedis.


Cream: 1%Rx, OTC

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)


  • Consult physician or other health care professional for proper cleansing technique before applying medication.
  • Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by physician or other health care professional.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes or vaginal area.
  • Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Early relief of symptoms may be seen in 2–3 days. For tinea cruris, tinea corporis, and tinea versicolor, 2 wk are needed, and for tinea pedis, therapeutic response may take 4 wk. Recurrent fungal infections may be a sign of systemic illness.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and.
  • Resolution of infection.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Two words: Lotrimin Ultra. That's the brand name for butenafine cream 1%, not to be confused with plain old Lotrimin, which is clotrimazole.
(+3.2%) LEADING BRANDS ** Market Dollar Dollar share sales sales % [000] change Private Label 29.5% $15,718 + 1.3% Cortizone 10 15.2% 8,069 + 7.5% Aveeno Active 6.8% 3,635 + 11.8% Naturals Benadryl 5.9% 3,127 + 3.5% Lotrimin AF 4.4% 2,346 + 4.9% Gold Bond 4.1% 2,181 + 40.1% Sarna 3.1% 1,622 + 14.0% Eucerin 3.0% 1,567 + 226% Cortizone 10 Plus 2.4% 1,250 2.5% Lotrimin Ultra 1.9% 983 - 19.4% TOTAL UNIT SALES * 19.9 mil.
(+3.9%) Dollar Dollar LEADING Market sales sales BRANDS ** share (000) % change Cortizone 10 7.9% $16,044 + 19.5% Benadryl 7.9% 15,960 + 4.1% Sarna 4.9% 9,899 + 6.1% Aveeno 4.9% 9,842 - 12.5% Cortaid 4.4% 8,859 - 19.7% Cortizone 10 Plus 3.8% 7,590 + 7.2% Lotrimin AF 3.2% 6,494 + 5.7% Zanfel 2.4% 4,774 - 6.7% Lotrimin Ultra 2.0% 4,066 + 2.3% Gold Bond 2.0% 3.94 - 7.6% TOTAL UNIT SALES* 53.9 mil.
Scholl's Schering-Plough 4.0% 6,578 Lotrimin Ultra Schering-Plough 3.8% 6,394 Reclaim AF NDC Laboratories 3.0% 4,925 Miracle of Aloe Miracle of Aloe 2.9% 4,860 Flexitol Eulacto USA 2.7% 4,419 Gold Bond Chattem 2.5% 4,188 Desenex Novartis 2.4% Market Unit sales Leading brands ** Manufacturer share (000) Lamisil AT Novartis 8.9% 1,971 Lotrimin AF Schering-Plough 8.2% 1,819 Tinactin Schering-Plough 7.6% 1,674 Dr.
markets Lotrimin AF, Lotrimin Ultra, Tinactin and Dr.
commands second, third and fourth place with its Lotrimin AF, Tinactin and Lotrimin Ultra brands, respectively.
Schering-Plough recently extended the Lotrimin line by launching Lotrimin Ultra, which is designed to deliver rapid and effective treatment for athlete's foot, jock itch and ringworm.
Scholl's Advantage Schering-Plough 2.9% 8,473 Lotrimin Ultra Schering-Plough 2.2% 6,433 Dr.